switching glp 1 agonists between GLP‐1 receptor in clinical practice: Expert consensus and practical guidance PDF] Switching Between Glucagon-Like Peptide-1

In a review study from Denmark, also analyzed by Fessel, dementia risk was lowered by 53% when patients with Type 2 diabetes on GLP-1s were compared to patients on placebo

Im going to walk you through the mechanistic differences, clinical evidence, metabolic outcomes, and practical considerations that actually matter in the Retatrutide vs Cagrilintide debate

!

Peptides are not steroids , not stimulants, and not one-size-fits-all

"The androgen receptor acetylation site regulates cAMP and AKT but not ERK-induced activity"

Saeidi N, Meoli L, Nestoridi E, Gupta NK, Kvas S, Kucharczyk J, Bonab AA, Fischman AJ, Yarmush ML, Stylopoulos N